Drug
Her3 Dxd
Her3 Dxd: highest development phase Phase 1, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| HER3-DXd (FL-DP) NCT03260491 | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Her3 Dxd on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.